Certa Therapeutics appoints Dr Gareth Lewis as Chief Commercial Officer

Melbourne, Australia, 01 July 2022: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to announce the appointment of Dr Gareth Lewis as Chief Commercial Officer.

Dr Lewis joins Certa Therapeutics with over 25 years of R&D experience spanning drug and clinical development, portfolio strategy, pre-launch commercialisation, business development and licensing as well as on-market commercial responsibility. He completed a PhD in Chemistry at the University of Bristol in the UK and was awarded a Royal Society Fellowship to undertake postdoctoral research at the University of New South Wales, Sydney.

Having worked in a range of therapeutic areas, Dr Lewis’ development and commercialisation expertise includes numerous products and technologies, with broad multinational experience from time working in Australia, USA, Europe and Asia Pacific.

Dr Lewis’ pharmaceutical career started with AstraZeneca in the UK and Sweden, before moving to the Australian biotech sector. After gaining additional experience with generic injectable products at Hospira, he moved to Mayne Pharma, undertaking successive commercial leadership roles with increasing executive responsibilities in Australia and the USA.

As the Chief Commercial Officer at Certa Therapeutics, Dr Lewis will be responsible for the strategic development and commercialisation of the company’s drug candidate assets as well as leading all Corporate and Business Development activities.

“We are delighted to appoint Dr Lewis as Certa’s Chief Commercial Officer. With extensive experience in commercialisation, Dr Lewis’ strategic input as we continue with the development and commercialisation of the company’s drug candidate is timely,” said Professor Darren Kelly, Chief Executive Officer of Certa Therapeutics.